- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-4/A Registration of securities issued in business combination transactions
- 5.1 Opinion of Ellenoff Grossman & Schole LLP
- 8.1 Tax Opinion of Ellenoff Grossman & Schole LLP
- 10.15 Offer Letter, Dated As of July 18, 2016, by and Between Blade Theraueptics, Inc. and Wendye Robbins, M.D
- 10.16 Offer Letter, Dated As of February 1, 2021, by and Between Blade Therapeutics, Inc. and Jean-frederic Viret, PH.D
- 10.17 Offer Letter, Dated As of April 19, 2017, by and Between Blade Therapeutics, Inc. and Prabha Ibrahim, PH.D
- 10.18 Offer Letter, Dated As of September 30, 2016, by and Between Blade Therapeutics, Inc. and Felix Karim, PH.D
- 10.19 Amendment to Offer Letter, Dated As of March 24, 2022, by and Between Blade Biotherapeutics, Inc. and Wendye Robbins, M.D
- 10.20 Amendment to Offer Letter, Dated As of March 24, 2022, by and Between Blade Biotherapeutics, Inc. and Jean-frederic Viret, PH.D
- 10.21 Amendment to Offer Letter, Dated As of March 24, 2022, by and Between Blade Biotherapeutics, Inc. and Prabha Ibrahim, PH.D
- 10.22 Amendment to Offer Letter, Dated As of March 24, 2022, by and Between Blade Biotherapeutics, Inc. and Felix Karim, PH.D
- 23.1 Consent of Marcum LLP
- 23.2 Consent of Ernst and Young LLP, Independent Registered Accounting Firm for Blade Therapeutics, Inc
- 99.2 Consent of Wendye Robbins to Be Named As a Director
- 99.3 Consent of Mark Timney to Be Named As a Director
- 99.4 Consent of Lloyd Klickstein to Be Named As a Director
- 99.5 Consent of James Scopa to Be Named As a Director
- 99.6 Consent of Luke Evnin to Be Named As a Director
- 99.7 Consent of John A. Hohneker, M.D. to Be Named As a Director
- 99.8 Consent of Carl Goldfischer, M.D. to Be Named As a Director
- Download Excel data file
- View Excel data file
- 17 Jun 22 RW Registration withdrawal request
- 23 May 22 424B3 Prospectus supplement
- 10 May 22 EFFECT Notice of effectiveness
- 9 May 22 424B3 Prospectus supplement
- 9 May 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 3 May 22 S-4/A Registration of securities issued in business combination transactions (amended)
-
15 Apr 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 1 Apr 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 15 Mar 22 S-4 Registration of securities issued in business combination transactions
Exhibit 23.1
Independent Registered Public Accounting Firm’s Consent
We consent to the inclusion in this Registration Statement of Biotech Acquisition Company on Amendment No. 2 to Form S-4 (File No. 333-263577) of our report dated March 7, 2022, which includes an explanatory paragraph as to Biotech Acquisition Company’s ability to continue as a going concern, with respect to our audits of the consolidated financial statements of Biotech Acquisition Company as of December 31, 2021 and 2020 and for the year ended December 31, 2021 and for the period from September 3, 2020 (inception) through December 31, 2020, which report appears in the proxy statement/prospectus, which is part of this Registration Statement. We also consent to the reference to our Firm under the heading “Experts” in such proxy statement/prospectus.
/s/ Marcum llp
Marcum llp
Philadelphia, Pennsylvania
April 15, 2022